(AMBEA) Ambea - Ratings and Ratios
Elderly Care, Disability Care, Psychosocial Support, Nursing Homes, Home Care
AMBEA EPS (Earnings per Share)
AMBEA Revenue
Description: AMBEA Ambea
Ambea AB is a leading provider of elderly care, disability care, and psychosocial support services in Sweden, Norway, and Denmark, operating through multiple brands, including Nytida, Vardaga, Stendi, Altiden, and Klara. The companys diverse service portfolio includes social care services, schools for children with neuropsychiatric disorders, nursing homes, home care services, and staff solutions for social welfare services.
To evaluate Ambeas performance, key performance indicators (KPIs) such as revenue growth, operating margin, and return on equity (RoE) are crucial. With a reported RoE of 12.91%, Ambea demonstrates a relatively strong ability to generate profits from shareholder equity. Additionally, the companys market capitalization of 9957.59M SEK and a price-to-earnings ratio (P/E) of 16.13 suggest a moderate valuation. Other relevant KPIs could include occupancy rates in nursing homes, customer satisfaction scores, and employee retention rates, which are not publicly disclosed in the given data.
From a strategic perspective, Ambeas diversified brand portfolio and geographic presence in multiple Nordic countries provide a solid foundation for growth. The companys focus on developing skills development training and coaching services under the Lära brand and care facilities under the Validia brand indicates a commitment to expanding its service offerings and addressing the complex needs of its target demographic. To further assess Ambeas prospects, analyzing its historical financial performance, industry trends, and competitive landscape would be essential.
To make an informed investment decision, it is crucial to monitor Ambeas future performance and adjust expectations accordingly. Key areas to watch include the companys ability to maintain its operating margin, expand its customer base, and adapt to regulatory changes in the healthcare sector. By closely tracking these factors and relevant KPIs, investors can make more informed decisions about Ambeas stock.
AMBEA Stock Overview
| Market Cap in USD | 1,229m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception |
AMBEA Stock Ratings
| Growth Rating | 72.8% |
| Fundamental | 70.4% |
| Dividend Rating | 55.5% |
| Return 12m vs S&P 500 | 26.1% |
| Analyst Rating | - |
AMBEA Dividends
| Dividend Yield 12m | 1.90% |
| Yield on Cost 5y | 4.23% |
| Annual Growth 5y | 6.87% |
| Payout Consistency | 75.0% |
| Payout Ratio | 29.7% |
AMBEA Growth Ratios
| Growth Correlation 3m | 84% |
| Growth Correlation 12m | 94.3% |
| Growth Correlation 5y | 38.3% |
| CAGR 5y | 19.68% |
| CAGR/Max DD 5y | 0.34 |
| Sharpe Ratio 12m | 0.95 |
| Alpha | 32.27 |
| Beta | 0.818 |
| Volatility | 40.25% |
| Current Volume | 213.3k |
| Average Volume 20d | 188.4k |
| Stop Loss | 123.4 (-3.3%) |
| Signal | 0.36 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (624.0m TTM) > 0 and > 6% of Revenue (6% = 895.4m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -1.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -15.35% (prev -13.38%; Δ -1.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 1.91b > Net Income 624.0m (YES >=105%, WARN >=100%) |
| Net Debt (3.54b) to EBITDA (2.07b) ratio: 1.71 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (81.9m) change vs 12m ago -5.69% (target <= -2.0% for YES) |
| Gross Margin 78.49% (prev 55.85%; Δ 22.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 74.89% (prev 74.35%; Δ 0.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.16 (EBITDA TTM 2.07b / Interest Expense TTM 481.0m) >= 6 (WARN >= 3) |
Altman Z'' -0.59
| (A) -0.11 = (Total Current Assets 2.31b - Total Current Liabilities 4.60b) / Total Assets 21.34b |
| (B) -0.05 = Retained Earnings (Balance) -1.10b / Total Assets 21.34b |
| (C) 0.05 = EBIT TTM 1.04b / Avg Total Assets 19.93b |
| (D) -0.07 = Book Value of Equity -1.10b / Total Liabilities 16.32b |
| Total Rating: -0.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.36
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 11.70% = 5.0 |
| 3. FCF Margin 11.89% = 2.97 |
| 4. Debt/Equity 0.76 = 2.22 |
| 5. Debt/Ebitda 1.83 = 0.33 |
| 6. ROIC - WACC 2.99% = 3.74 |
| 7. RoE 12.70% = 1.06 |
| 8. Rev. Trend 93.73% = 4.69 |
| 9. Rev. CAGR 9.48% = 1.18 |
| 10. EPS Trend 39.70% = 0.99 |
| 11. EPS CAGR -18.56% = -2.32 |
What is the price of AMBEA shares?
Over the past week, the price has changed by -7.33%, over one month by +3.66%, over three months by +17.28% and over the past year by +49.19%.
Is Ambea a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMBEA is around 135.31 SEK . This means that AMBEA is currently overvalued and has a potential downside of 6.04%.
Is AMBEA a buy, sell or hold?
What are the forecasts/targets for the AMBEA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 147.5 | 15.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 149.5 | 17.1% |
AMBEA Fundamental Data Overview
Market Cap SEK = 11.62b (11.62b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 247.0m SEK (Cash only, last quarter)
P/E Trailing = 18.6757
P/S = 0.7723
P/B = 2.2827
Beta = 0.927
Revenue TTM = 14.92b SEK
EBIT TTM = 1.04b SEK
EBITDA TTM = 2.07b SEK
Long Term Debt = 1.79b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.00b SEK (from shortLongTermDebt, last quarter)
Debt = 3.79b SEK (Calculated: Short Term 2.00b + Long Term 1.79b)
Net Debt = 3.54b SEK (from netDebt column, last quarter)
Enterprise Value = 15.17b SEK (11.62b + Debt 3.79b - CCE 247.0m)
Interest Coverage Ratio = 2.16 (Ebit TTM 1.04b / Interest Expense TTM 481.0m)
FCF Yield = 11.70% (FCF TTM 1.77b / Enterprise Value 15.17b)
FCF Margin = 11.89% (FCF TTM 1.77b / Revenue TTM 14.92b)
Net Margin = 4.18% (Net Income TTM 624.0m / Revenue TTM 14.92b)
Gross Margin = 78.49% ((Revenue TTM 14.92b - Cost of Revenue TTM 3.21b) / Revenue TTM)
Tobins Q-Ratio = -13.81 (set to none) (Enterprise Value 15.17b / Book Value Of Equity -1.10b)
Interest Expense / Debt = 3.51% (Interest Expense 133.0m / Debt 3.79b)
Taxrate = 23.65% (from yearly Income Tax Expense: 192.0m / 812.0m)
NOPAT = 792.6m (EBIT 1.04b * (1 - 23.65%))
Current Ratio = 0.50 (Total Current Assets 2.31b / Total Current Liabilities 4.60b)
Debt / Equity = 0.76 (Debt 3.79b / last Quarter total Stockholder Equity 5.02b)
Debt / EBITDA = 1.83 (Net Debt 3.54b / EBITDA 2.07b)
Debt / FCF = 2.14 (Debt 3.79b / FCF TTM 1.77b)
Total Stockholder Equity = 4.91b (last 4 quarters mean)
RoA = 2.92% (Net Income 624.0m, Total Assets 21.34b )
RoE = 12.70% (Net Income TTM 624.0m / Total Stockholder Equity 4.91b)
RoCE = 15.48% (Ebit 1.04b / (Equity 4.91b + L.T.Debt 1.79b))
RoIC = 10.46% (NOPAT 792.6m / Invested Capital 7.58b)
WACC = 7.47% (E(11.62b)/V(15.41b) * Re(9.03%)) + (D(3.79b)/V(15.41b) * Rd(3.51%) * (1-Tc(0.24)))
Shares Correlation 5-Years: 0.0 | Cagr: 0.41%
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.73% ; FCFE base≈1.81b ; Y1≈2.16b ; Y5≈3.38b
Fair Price DCF = 572.5 (DCF Value 48.15b / Shares Outstanding 84.1m; 5y FCF grow 20.10% → 3.0% )
Revenue Correlation: 93.73 | Revenue CAGR: 9.48%
Rev Growth-of-Growth: 2.84
EPS Correlation: 39.70 | EPS CAGR: -18.56%
EPS Growth-of-Growth: -40.40